#su11248 | Explore Tumblr Posts and Blogs

brokenlikeglass · 1 year

Text

2K notes · View notes

i-love--you · 1 year

Text

i want to 4tt3mpt again so fucking badly

50 notes · View notes

fagjunki3 · 2 years

Text

oh of course its okay. everything is always okay. im fine. im always fine. no need to bother. im fine. everything is good. everything is okay. everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything is okay everything. is okay. i. am okay. dont you dare to worry about me. ever

36 notes · View notes

im-nothing-and-n0body · 2 years

Text

Yeah I’m a problem solver. When a minor inconvenience happens I try to kill myself

#self destruction #su1c1d3 #su1c1d4l #self mutalition #sewerslidal #mental illness #mentally fucked #self h@te #tw depressing stuff #4na diary #self h@rm #su11248

17 notes · View notes

oppy-s-venting · 1 year

Text

Sometimes it feelslike there is a ball in my throat and I can't take a breath

Other times I'm very disappointed when I finally manage to

#su11248 #su1c1dal #depressao #kinda depressing #anxi4ty

3 notes · View notes

georgepowell58 · 1 year

Text

Hemorrhaging Throughout Dental Anticoagulation

001). Both of these strategies to evaluating remedy result have been very correlated (s smaller as compared to Zero.001). CEA proportion was found becoming a dependable prognostic factor in phase Four CRC, and was very correlated with all the image survey based on RECIST conditions. Additional future research is essential to verify these bits of information.Tomato (Solanum lycopersicum) berry accumulate the particular red carotenoid pigment lycopene. Your recessive mutation yellow-flesh (locus 3rd r) within tomato eliminates berry carotenoids through interfering with the activity in the fruit-specific phytoene synthase (PSY1), the very first devoted step up the carotenoid biosynthesis process. Many fruits from the recessive mutation tangerine (t) seem orange because of accumulation of seven,In search of,7', 9'-tetra-cis-lycopene (prolycopene) on account of a mutation from the carotenoid cis-trans isomerase. It had been proven Sixty b back which tangerine is epistatic for you to yellow-flesh. This particular uncharacteristic epistasis connection contradicts a new paradigm in biochemical inherited genes fighting which versions in which disturb digestive support enzymes performing early in the biosynthetic pathway tend to be epistatic with strains that block downstream steps in precisely the same pathway. To spell out this specific quandary, we've got investigated the particular discussion among tangerine and also yellow-flesh on the molecular level. Benefits shown the following suggest which allele ur(2997) of yellow-flesh eliminates transcription associated with PSY1 inside fresh fruits. In a anatomical background regarding tangerine, transcribing regarding PSY1 is actually partially refurbished to a stage sufficient for producing phytoene along with downstream carotenoids. Each of our benefits unveiled the actual molecular device main the actual epistasis involving t around third as well as propose the engagement of cis-carotenoid metabolites inside a comments unsafe effects of PSY1 gene appearance.Personal computers are structured directly into hardware and software. Employing a theoretical procedure for discover patterns inside this website gene term in several species, bodily organs, and mobile sorts, we all discovered that organic techniques in the same manner consist of a somewhat unchanging hardware-like gene structure. Orthogonal patterns associated with software-like transcripts vary greatly, actually amongst tumors of the identical variety from different individuals. 2 distinct lessons could possibly be discovered inside the hardware-like aspect: those records which are extremely depicted along with dependable as well as an adaptable part together with decrease term that reply to exterior stimulating elements. Essentially, we all show this composition is protected over microorganisms. Deletions of records through the remarkably stable primary tend to be forecasted for you to cause mobile or portable fatality. The actual approach gives a visual thermodynamic-like platform for your evaluation involving gene-expression amounts as well as networks and their versions inside diseased tissues.Any vulnerable, specific along with exact quantitative liquefied chromatography/tandem muscle size spectrometry (LC-MS/MS) way of the way of measuring of sunitinib (SU11248) and N-desethyl sunitinib (SU12662) within individual plasma tv's was created and confirmed. All taste handling was completed below rigorous mild protection.

0 notes

coolluminaryland-blog1 · 5 years

Text

Angiosarcomas Treatment Market to Register Substantial Expansion by 2024

Rare and clinically highly variable, Sarcoma is a type of cancer that originates from mesenchymal cells transformation. Sarcoma defines as the major tumors, such as bone, breast, skin, fats and soft tissues. One such rare type of soft tissue tumor is called as Angiosarcomas. This tumor begins to grow in the cells of a blood vessels and can occur in any part of body. Angiosarcoma tumors involve rapidly proliferating cancerous cells originated from endothelial or mesenchymal sources and develop blood filled channels. Angiosarcoma harbors is the worst prognosis among all sarcoma subtypes.

Read Report Overview: https://www.transparencymarketresearch.com/angiosarcomas-treatment-market.html

Angiosarcomas treatment market classification

Depending on the instigation of tumor, Angiosarcomas are classified as hemagiosarcoma (begin in blood vessels) and lymphangiosarcome (tumor begins in lymph vessels). The major causes of the disease are unknown, however, lymphederma is considered as a key propeller of the disease condition. In addition to this, frequent and long term exposure of the radiation is also considered as an important cause.

The major symptoms include skin infections; however, the deeply situated tumors may not show any distinct symptom of the disease. The latter condition worsens the situation and may be a fatal one. The diagnostic procedures mainly include CT, MRI and PET scan. In addition, biopsy procedure has proved its effectiveness in the disease diagnosis. This disease has a very low incidence rate of 2-3 per million people and also occurs in patients of breast cancer who have undergone radiation therapy.

Angiosarcomas treatment market remedies

Angiosarcoma treatment requires medical attention from a multidisciplinary medical team and includes oncologists, surgeons and other medical team. The disease is treated primarily with surgical intervention. Chemotherapy is also used due to high risk of local relapse and distant metastatic disease. However, chemotherapy and radiation therapy are critical for treating Angiosarcomas before and after surgery. The most common chemotherapeutic drug for treating Angiosarcomas includes doxorubicin.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14942

However, combination therapy involving mesna, doxorubicin, and ifosfamide has also shown effectiveness against Angiosarcomas. There have been several attempts in last decade to develop drugs that target blood vessels growth stimulator VEGF and thereby cause shrinking of angiosarcomas. These drugs include bevacizumab, irinotecan, sildenafil, SU11248, BAY43-9006, and AMG706. Radiation therapy includes exposure of high power gamma and X-rays to irradiate the tumors.

Angiosarcomas treatment market research

In a recent research at University of North Carolina, researcher reported a monoclonal antibody targeted towards a protein known as SFRP2 found to inhibit growth of angiosarcoma. The study was initiated because SFRP2 acts as a potent stimulator of angiogenesis and it was therefore hypothesized that targeting SFRP2 could inhibit tumor growth. The study is still in very nascent stage and will enter into clinical trials provided the researchers obtain enough funding for their research. The major drivers of the market include steadily increasing prevalence of the disease. Although the disease is considered as rare (less than 1 percent of the sarcoma diagnosed population), the prevalence is increasing steadily. This is anticipated to drive the market during forecast period 2014 – 2020. In addition, extensive R&D practices also fuels the market growth. A number of drugs, such as, AMG-386, sildenafil, and many others are under pipeline studies and expected to enter in the market in coming 5-10 years. A major restraint in developing specific drug for treating Angiosarcomas is the limited number of people on which the drug can be tested to confirm its safety and efficacy. Angiosarcomas are so rare accounting for only 1% of sarcomas which in turn account for only 1 percent of all kinds of cancer.

Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=14942

The major players operating in the global Angiosarcomas market include Pfizer, Inc., Genentech, Inc., Bayer Healthcare, Janssen Products, LP, Sanofi S.A., and Amgen, Inc.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 USA – Canada Toll Free 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com/

0 notes

healthcareresearch010-blog · 5 years

Text

Angiosarcomas Treatment Market Projected to Gain Significant Value by 2024

Rare and clinically highly variable, Sarcoma is a type of cancer that originates from mesenchymal cells transformation. Sarcoma defines as the major tumors, such as bone, breast, skin, fats and soft tissues. One such rare type of soft tissue tumor is called as Angiosarcomas. This tumor begins to grow in the cells of a blood vessels and can occur in any part of body. Angiosarcoma tumors involve rapidly proliferating cancerous cells originated from endothelial or mesenchymal sources and develop blood filled channels. Angiosarcoma harbors is the worst prognosis among all sarcoma subtypes.

Depending on the instigation of tumor, Angiosarcomas are classified as hemagiosarcoma (begin in blood vessels) and lymphangiosarcome (tumor begins in lymph vessels). The major causes of the disease are unknown, however, lymphederma is considered as a key propeller of the disease condition. In addition to this, frequent and long term exposure of the radiation is also considered as an important cause.

View Report –

https://www.transparencymarketresearch.com/angiosarcomas-treatment-market.html

The major symptoms include skin infections; however, the deeply situated tumors may not show any distinct symptom of the disease. The latter condition worsens the situation and may be a fatal one. The diagnostic procedures mainly include CT, MRI and PET scan. In addition, biopsy procedure has proved its effectiveness in the disease diagnosis. This disease has a very low incidence rate of 2-3 per million people and also occurs in patients of breast cancer who have undergone radiation therapy.

Angiosarcoma treatment requires medical attention from a multidisciplinary medical team and includes oncologists, surgeons and other medical team. The disease is treated primarily with surgical intervention. Chemotherapy is also used due to high risk of local relapse and distant metastatic disease. However, chemotherapy and radiation therapy are critical for treating Angiosarcomas before and after surgery.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14942

The most common chemotherapeutic drug for treating Angiosarcomas includes doxorubicin. However, combination therapy involving mesna, doxorubicin, and ifosfamide has also shown effectiveness against Angiosarcomas. There have been several attempts in last decade to develop drugs that target blood vessels growth stimulator VEGF and thereby cause shrinking of angiosarcomas. These drugs include bevacizumab, irinotecan, sildenafil, SU11248, BAY43-9006, and AMG706. Radiation therapy includes exposure of high power gamma and X-rays to irradiate the tumors.

In a recent research at University of North Carolina, researcher reported a monoclonal antibody targeted towards a protein known as SFRP2 found to inhibit growth of angiosarcoma. The study was initiated because SFRP2 acts as a potent stimulator of angiogenesis and it was therefore hypothesized that targeting SFRP2 could inhibit tumor growth. The study is still in very nascent stage and will enter into clinical trials provided the researchers obtain enough funding for their research. The major drivers of the market include steadily increasing prevalence of the disease.

Although the disease is considered as rare (less than 1 percent of the sarcoma diagnosed population), the prevalence is increasing steadily. This is anticipated to drive the market during forecast period 2014 – 2020. In addition, extensive R&D practices also fuels the market growth. A number of drugs, such as, AMG-386, sildenafil, and many others are under pipeline studies and expected to enter in the market in coming 5-10 years. A major restraint in developing specific drug for treating Angiosarcomas is the limited number of people on which the drug can be tested to confirm its safety and efficacy. Angiosarcomas are so rare accounting for only 1% of sarcomas which in turn account for only 1 percent of all kinds of cancer.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=14942

The major players operating in the global Angiosarcomas market include Pfizer, Inc., Genentech, Inc., Bayer Healthcare, Janssen Products, LP, Sanofi S.A., and Amgen, Inc.

0 notes

awesomerohitpatilme-blog · 6 years

Text

Angiosarcomas Treatment Market :Growth and Sales Forecast 2016-2024

Rare and clinically highly variable, Sarcoma is a type of cancer that originates from mesenchymal cells transformation. Sarcoma defines as the major tumors, such as bone, breast, skin, fats and soft tissues. One such rare type of soft tissue tumor is called as Angiosarcomas. This tumor begins to grow in the cells of a blood vessels and can occur in any part of body. Angiosarcoma tumors involve rapidly proliferating cancerous cells originated from endothelial or mesenchymal sources and develop blood filled channels. Angiosarcoma harbors is the worst prognosis among all sarcoma subtypes.

View Report-

https://www.transparencymarketresearch.com/angiosarcomas-treatment-market.html

Angiosarcomas treatment market classification

Depending on the instigation of tumor, Angiosarcomas are classified as hemagiosarcoma (begin in blood vessels) and lymphangiosarcome (tumor begins in lymph vessels). The major causes of the disease are unknown, however, lymphederma is considered as a key propeller of the disease condition. In addition to this, frequent and long term exposure of the radiation is also considered as an important cause.

The major symptoms include skin infections; however, the deeply situated tumors may not show any distinct symptom of the disease. The latter condition worsens the situation and may be a fatal one. The diagnostic procedures mainly include CT, MRI and PET scan. In addition, biopsy procedure has proved its effectiveness in the disease diagnosis. This disease has a very low incidence rate of 2-3 per million people and also occurs in patients of breast cancer who have undergone radiation therapy.

Request For Custom Research-

https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=14942

Angiosarcomas treatment market remedies

Angiosarcoma treatment requires medical attention from a multidisciplinary medical team and includes oncologists, surgeons and other medical team. The disease is treated primarily with surgical intervention. Chemotherapy is also used due to high risk of local relapse and distant metastatic disease. However, chemotherapy and radiation therapy are critical for treating Angiosarcomas before and after surgery. The most common chemotherapeutic drug for treating Angiosarcomas includes doxorubicin. However, combination therapy involving mesna, doxorubicin, and ifosfamide has also shown effectiveness against Angiosarcomas. There have been several attempts in last decade to develop drugs that target blood vessels growth stimulator VEGF and thereby cause shrinking of angiosarcomas. These drugs include bevacizumab, irinotecan, sildenafil, SU11248, BAY43-9006, and AMG706. Radiation therapy includes exposure of high power gamma and X-rays to irradiate the tumors.

Angiosarcomas treatment market research

In a recent research at University of North Carolina, researcher reported a monoclonal antibody targeted towards a protein known as SFRP2 found to inhibit growth of angiosarcoma. The study was initiated because SFRP2 acts as a potent stimulator of angiogenesis and it was therefore hypothesized that targeting SFRP2 could inhibit tumor growth. The study is still in very nascent stage and will enter into clinical trials provided the researchers obtain enough funding for their research. The major drivers of the market include steadily increasing prevalence of the disease. Although the disease is considered as rare (less than 1 percent of the sarcoma diagnosed population), the prevalence is increasing steadily. This is anticipated to drive the market during forecast period 2014 – 2020. In addition, extensive R&D practices also fuels the market growth. A number of drugs, such as, AMG-386, sildenafil, and many others are under pipeline studies and expected to enter in the market in coming 5-10 years. A major restraint in developing specific drug for treating Angiosarcomas is the limited number of people on which the drug can be tested to confirm its safety and efficacy. Angiosarcomas are so rare accounting for only 1% of sarcomas which in turn account for only 1 percent of all kinds of cancer.

Brochure Download-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14942

The major players operating in the global Angiosarcomas market include Pfizer, Inc., Genentech, Inc., Bayer Healthcare, Janssen Products, LP, Sanofi S.A., and Amgen, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453

Email: [email protected]

Website: http://www.transparencymarketresearch.com/

#Rare and clinically highly variable Sarcoma is a type of cancer that originates from mesenchymal cells transformation. Sarcoma defines as th

0 notes

healthcareanalystinsights-blog · 7 years

Text

Angiosarcomas Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017–2025

Angiosarcomas Treatment Market :

Sarcoma is a group of soft tissue tumors and a rare and clinically variable type of cancer that originates due to the transformation of mesenchymal cells. Angiosarcomas mainly occurs in the breast, bone, skin, soft tissues, and spleen. It grows in the cells of blood vessels and spreads into various parts of the body that affects the normal activity. This type of tumor has rapidly multiplying cancerous cells, which originated from mesenchymal or endothelial source. Such tumors typically appears on skin and face and while high growth of these tumors they can increases the risk of mortality. The severity and spreading area of the disease is projected to be one of the major cause that will support growth of the angiosarcomas treatment market over the forecast period.

Get an exclusive sample of this report : https://www.coherentmarketinsights.com/insight/request-sample/396

There are various types of angiosarcomas such as Epithelioid Angiosarcoma, Cardiac Angiosarcoma, Hepatic Angiosarcoma and Cutaneous Angiosarcoma. As per the stats of Know Cancer (this institute known for connecting cancer infected people to empower and educate them about cancer) cutaneous angiosarcomas contributes to the maximum of angiosarcomas cases, which is around 60% followed by angiosarcomas found in deep tissue and in breast tissue contributes around 35% in overall cases. Skin lesions, bone pain, fatigue, anemia and heart pain are some symptoms of angiosarcomas, though these vary according to location of angiosarcomas.

The treatment options available for angiosarcomas are surgery, chemotherapy and radiotherapy. Furthermore, according to the National Cancer Institute (NCI), the survival rate is around 5 year after diagnosis which is found in 50% of the people having angiosarcomas. The people who respond to treatment and show some recovery in first 5 years after diagnosis of angiosarcomas, have more chances of survival. According to the data published by NCI in 2014, based on 5 years study the survival rate for sarcoma was pegged at 90% those in first stage, 81% at second stage, 56% during third stage and during fourth stage there is no survival rate available. Also, some diagnostics tests such as CT, PET, MRI scan and biopsy test for the effective diagnosis of angiosarcomas.

As per results of a study by Coherent Market Insights, in August 2015, the incidence rate for this disease is very low, with angiosarcomas contributing 1-2% towards sarcoma cases. Rapid surge in number of cancer cases worldwide inadvertently creates a highly conducive environment for growth of the angiosarcomas treatment market.

As per the stats published by European Medicines Agency in January, there are around 3.5 in 10,000 people affected by angiosarcomas in Europe, in 2016. While in U.S. as per the stats of Know Cancer, angiosarcomas account for only 0.7% of cancer cases which makes it very rare type of cancer.

Angiosarcomas treatment market taxonomy:

Global Market by location of Instigation

Hemangiosarcoma

Lymphangiosarcoma

Global Market by Type of Treatment

Surgery

Chemotherapy

Radiotherapy

Global Market by Geography

North America

Europe

APAC

Latin America

Middle East

Africa

Expected rise in prevalence of angiosarcomas disease and increase in research and development into cancer treatment drugs are the major factors driving the growth of angiosarcomas treatment market

As the major research and development activities in the area of cancer are mostly performed in North America region, it holds the major market share of angiosarcomas treatment market followed by Europe backboned by increased healthcare infrastructure development, affordability of drugs, developed treatment options and high awareness about available treatments.

Increase in number of cancer cases and growing awareness regarding the treatments in emerging economies are expected to contribute majorly in the growth of angiosarcomas treatment market. Furthermore, growth in per capita income is projected to support the high health care spending by the population, which in turn is expected to favor the growth in angiosarcomas treatment industry in the near future.

As the disease is rare, only few organizations are investing in research and development and high cost of the drugs are the growth restraining factors of market in angiosarcomas treatment. However, considering the projected increase in incidence of the disease in the near future, the market is expected to witness the entry of various new players.

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/396

Major companies involved in the angiosarcomas treatment market include Genentech, Inc., Pfizer Inc., Janssen Global Services, LLC, Bayer AG, Sanofi, Amgen Inc., also some innovative leading drugs include irinotecan, sildenafil, bevacizumab, BAY43-9006, and SU11248.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:[email protected]

Website:https://www.coherentmarketinsights.com

#Angiosarcomas Treatment Market #Angiosarcomas Treatment Industry Insights #Angiosarcomas Treatment Market Trends

0 notes

brokenlikeglass · 1 year

Text

52 notes · View notes

brokenlikeglass · 1 year

Text

i genuinely do not want to exist anymore. i get talked over and ignored so even if i was gone no one would notice or care. they wouldn’t notice shit.

#tw depressing stuff #su1cide #su1c1d4l #sorry for being depressing #depressing shit #tw ana related #anor3x14 #anxeity #depressing quotes #deppresion #kinda depressing #tw ed vent #tw ed rant #disordered eating in tags #ed but not sheeran #su11248 #su1c1dal #su1c1d3 #tw selfhate

39 notes · View notes

brokenlikeglass · 1 year

Text

it’s sad how easy it is to fake laugh. i really don’t want to do this anymore. i’m literally numb and i’m so close to giving up.

22 notes · View notes

brokenlikeglass · 1 year

Text

i need to stop eating. i want to stop eating. please stop eating.

and yet i still ate a meal i’m fucking disgusting

28 notes · View notes

brokenlikeglass · 1 year

Text

30 notes · View notes

brokenlikeglass · 1 year

Text

it hurts so much, i just want it all to end

18 notes · View notes